tirzepatide vs. semaglutide for weight loss vs Semaglutide: 2026 Clinical Comparison Tirzepatide vs. Semaglutide: Understanding Your

However, there is the potential for DDIs of GLP-1 RAs to occur through their mechanisms of action

Nutrients , 13(11), 3831

These complex responses lead to the loss of Beclin 1 and class III PI3K complex function, further affecting autophagic function

These lawsuits assert legal theories including: Trademark infringement Violating the corporate practice of medicine doctrine False advertising Unfair competition Violations of federal drug laws (misbranding, unapproved new drugs) FDA Enforcement On February 6, 2026, FDA announced its intent to use all available compliance and enforcement tools within its authorities to address unsubstantiated claims and associated public health concerns. The FDA explicitly announced steps to combat compounding pharmacies making these marketing claims: Compounded products are generic versions of FDA-approved drugs Compounded products are the same as FDA-approved drugs Compounded products use the same active ingredient as FDA-approved drugs Compounded products are clinically proven to produce results FDA has made clear that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. This means the agency may bypass traditional warning letter procedures